Mitomycin C and 5-fluorouracil as second choice treatment in advanced breast cancer patients.
Twenty-six patients with advanced breast cancer, (12 previously treated with adriamycin-containing regimens, 14 not exposed to adriamycin because of poor cardiac performance), were treated with combination chemotherapy including mitomycin C plus 5-fluorouracil. Objective response was seen in 7/66 patients (26.9%) with a statistically higher response rate in patients with fewer than 2 metastatic sites. Because of mild toxicity this regimen can be safely used as second-line chemotherapy for heavily pretreated patients and as first-line treatment in patients with poor cardiac performance.